信达生物:上半年总产品收入超52亿元 同比增长超过35%

格隆汇
Aug 07

信达生物(1801.HK)公布,2025年上半年公司共取得总产品收入超人民币52亿元,同比保持35%以上的强劲增长;其中2025年第二季度总产品收入超过人民币27亿元,同比增长超过30%。该季度的持续增长得益于肿瘤和综合管线双轮驱动共同发力,肿瘤治疗领域的领导品牌和产品组合强大,主要产品保持优异增长,新产品收入贡献持续提升;二季度末,全球首个胰高血糖素╱胰高血糖素样肽-1(GCG/GLP-1)双受体激动药物信尔美®(玛仕度肽注射液)的减重适应症亦获得中国国家药品监督管理局批准上市,为公司在综合产品线领域的布局再添一款重要品种。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10